Two years ago, researchers examining the link between GLP-1 and substance abuse began to publish large, observational studies showing that patients taking GLP-1s for their prescribed purposes incidentally reported less alcohol, opioid, cannabis and cigarette use and had a lower risk of developing a substance use disorder
The effectiveness of B12 is further enhanced when combined with energy-boosting properties
Exceeding 2,000mg per day may cause digestive upset, including bloating, loose stools, and cramping
New developments, such as dual and triple agonists that target the glucagon, GLP-1, and GIP receptors, promise better results
Different routes affect tissue exposure, signaling, and outcomes
The broad availability of subcutaneous GLP-1 products together with their strong clinical data are the main factors that have been driving this segment to lead on the global market